Аннотация:
Prevention of prostate cancer (PCa) is a vital problem dictated by the obvious benefit of prevention compared to the complexity of treatment. To date, a tremendous amount of research both in vitro, and in vivo assessment of different prophylactic measures has been published. They included consumption of protein, carbohydrate, fat, fiber, vegetable extracts and other solid products, and combinations thereof in the diet, vitamins, minerals, and biologically active substances, medicaments. The optimal preventive agent has not been found, and that prompted us to conduct our own research of dietary supplement ProstaDoz. The study was performed on a group of 58 patients with elevated prostate-specific antigen and the results of the histological study confirming the absence of prostate cancer and the presence of a high degree PIN. After 6 month course of ProstaDoz histological analysis of repeated biopsy samples revealed a significantly lower incidence of prostate cancer and atypical small acinar proliferation in the group receiving ProstaDoz (10.4[%]) compared to control group (20,7[%]; p <0,024), and in some cases even regression of PIN (32[%]) in the study group (p = 0.5). Also, there was a significant reduction in prostate-specific antigen after receiving ProstaDoz. These data show the potential effectiveness of ProstaDoz use as a means of PCa chemoprevention.
Alyaev Y.G. Yu G
Rapoport L.M.
Tsarichenko D.G.
Ganzha T.M.
Krupinov G.E.
Clinic of Urology, Sechenov First Moscow State Medical University Research Institute of Uronephrology and Human Reproductive Health.
Prostadoz opportunity for prostate cancer prevention?
Текст визуальный электронный
Urologiia (Moscow, Russia : 1999)
№ 6 С. 58-67
2015
ProstaDoz
prostate cancer prevention
Статья
Dietary Supplements G07.203.300.456 J02.500.456
Нутрицевтики G07.203.300.456 J02.500.456
Humans B01.050.150.900.649.313.988.400.112.400.400
Человек B01.050.150.900.649.313.988.400.112.400.400
Male
Мужской
Minerals D01.578
Минералы D01.578
Prostate-Specific Antigen D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.869.250.249.500 D23.050.285.625 D23.101.140.625
Предстательной железы специфический антиген D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.869.250.249.500 D23.050.285.625 D23.101.140.625
Prostatic Neoplasms C04.588.945.440.770 C12.100.500.260.750 C12.100.500.565.625 C12.200.294.260.750 C12.200.294.565.625 C12.200.758.409.750 C12.900.619.750
Prostatic Neoplasms prevention & control C04.588.945.440.770 C12.100.500.260.750 C12.100.500.565.625 C12.200.294.260.750 C12.200.294.565.625 C12.200.758.409.750 C12.900.619.750
Предстательной железы новообразования C04.588.945.440.770 C12.100.500.260.750 C12.100.500.565.625 C12.200.294.260.750 C12.200.294.565.625 C12.200.758.409.750 C12.900.619.750
Предстательной железы новообразования профилактика и контроль C04.588.945.440.770 C12.100.500.260.750 C12.100.500.565.625 C12.200.294.260.750 C12.200.294.565.625 C12.200.758.409.750 C12.900.619.750
Vitamins D27.505.696.494.600 G07.203.300.681.500.600 J02.500.681.500.600
Vitamins therapeutic use D27.505.696.494.600 G07.203.300.681.500.600 J02.500.681.500.600
Витамины D27.505.696.494.600 G07.203.300.681.500.600 J02.500.681.500.600
Витамины терапевтическое применение D27.505.696.494.600 G07.203.300.681.500.600 J02.500.681.500.600
Journal Article V02.600
Журнальная статья V02.600
Prevention of prostate cancer (PCa) is a vital problem dictated by the obvious benefit of prevention compared to the complexity of treatment. To date, a tremendous amount of research both in vitro, and in vivo assessment of different prophylactic measures has been published. They included consumption of protein, carbohydrate, fat, fiber, vegetable extracts and other solid products, and combinations thereof in the diet, vitamins, minerals, and biologically active substances, medicaments. The optimal preventive agent has not been found, and that prompted us to conduct our own research of dietary supplement ProstaDoz. The study was performed on a group of 58 patients with elevated prostate-specific antigen and the results of the histological study confirming the absence of prostate cancer and the presence of a high degree PIN. After 6 month course of ProstaDoz histological analysis of repeated biopsy samples revealed a significantly lower incidence of prostate cancer and atypical small acinar proliferation in the group receiving ProstaDoz (10.4[%]) compared to control group (20,7[%]; p <0,024), and in some cases even regression of PIN (32[%]) in the study group (p = 0.5). Also, there was a significant reduction in prostate-specific antigen after receiving ProstaDoz. These data show the potential effectiveness of ProstaDoz use as a means of PCa chemoprevention.